الاتحاد الأوروبي - الكرواتية - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - hepatitis a virus (inactivated), hepatitis b surface antigen - immunization; hepatitis b; hepatitis a - cjepiva - twinrix pedijatrijskih je indiciran za uporabu u sobe imunološki dojenčadi, djece i adolescenata od jedne godine do i uključujući 15 godina koji su u opasnosti od oba hepatitisa a i hepatitisa b infekcije.

الاتحاد الأوروبي - الكرواتية - EMA (European Medicines Agency)

takeda manufacturing austria ag - octocog alfa - hemofilija a - antihemorrhagics - liječenje i profilaksu krvarenja u bolesnika s hemofilijom a (nedostatak prirođenih faktora viii). advate ne sadrži faktor Виллебранда u farmakološki učinkovite količinama i stoga nije navedeno u ангиогемофилия .

الاتحاد الأوروبي - الكرواتية - EMA (European Medicines Agency)

abbvie deutschland gmbh co. kg - adalimumab - spondylitis, ankylosing; arthritis, juvenile rheumatoid; uveitis; colitis, ulcerative; psoriasis; arthritis, psoriatic; crohn disease; arthritis, rheumatoid - imunosupresivi - molimo pogledajte dokument s informacijama o proizvodu.

الاتحاد الأوروبي - الكرواتية - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, валсартан - zastoj srca - antagonisti angiotenzina ii, druge kombinacije, agenti koji djeluju na ренин-ангиотензиновую sustav - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

الاتحاد الأوروبي - الكرواتية - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, валсартан - zastoj srca - sredstva koja djeluju na sustav renin-angiotenzina - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.

الاتحاد الأوروبي - الكرواتية - EMA (European Medicines Agency)

bayer ag - riociguat - hipertenzija, plućna - antihipertenzivi za plućnu arterijsku hipertenziju - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. učinkovitost je dokazana u populaciji uh uključujući etiologija idiopatskom ili nasljedne ili uh uh, povezane s bolestima vezivnog tkiva . paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.

الاتحاد الأوروبي - الكرواتية - EMA (European Medicines Agency)

amgen europe b.v. - romiplostim - purpura, trombocitopenična, idiopatska - antihemorrhagics - adults:nplate is indicated for the treatment of primary immune thrombocytopenia  (itp) in adult patients who are refractory to other treatments (e. kortikosteroidi, imunoglobulini). paediatrics:nplate is indicated for the treatment of chronic primary immune thrombocytopenia (itp) in paediatric patients one year of age and older who are refractory to other treatments (e. kortikosteroidi, imunoglobulini).

الاتحاد الأوروبي - الكرواتية - EMA (European Medicines Agency)

eli lilly nederland b.v. - tadalafil - hipertenzija, plućna - urologicals - adultstreatment of pulmonary arterial hypertension (pah) classified as who functional class ii and iii, to improve exercise capacity (see section 5. učinkovitost je pokazana u idiopatskom pah (ipah) i pah povezanoj na vaskularnu bolest kolagena. paediatric populationtreatment of paediatric patients aged 2 years and above with pulmonary arterial hypertension (pah) classified as who functional class ii and iii.

الاتحاد الأوروبي - الكرواتية - EMA (European Medicines Agency)

sanofi winthrop industrie - teriflunomide - multipla skleroza - selektivni imunosupresivi - aubagio is indicated for the treatment of adult patients and paediatric patients aged 10 years and older with relapsing remitting multiple sclerosis (ms) (please refer to section 5. 1 for important information on the population for which efficacy has been established).

الاتحاد الأوروبي - الكرواتية - EMA (European Medicines Agency)

sandoz gmbh - epoetin alfa - anemia; kidney failure, chronic - antianemijski pripravci - treatment of symptomatic anaemia associated with chronic renal failure (crf) in adult and paediatric patients: , treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis;, treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis;, treatment of anaemia and reduction of transfusion requirements in adult patients receiving chemotherapy for solid tumours, malignant lymphoma or multiple myeloma, and at risk of transfusion as assessed by the patient's general status (e. stanje kardiovaskularnog sustava, već postojeće anemije u početku kemoterapije).